486 related articles for article (PubMed ID: 34718069)
1. Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study.
Kadali RAK; Janagama R; Yedlapati SH; Kanike N; Gajula V; Madathala RR; Poddar S; Sukka N; Jogu HR; Racherla S; Shah I
Am J Infect Control; 2022 Jan; 50(1):8-14. PubMed ID: 34718069
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
Kadali RAK; Janagama R; Peruru S; Malayala SV
Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
[TBL] [Abstract][Full Text] [Related]
6. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
7. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
Kadali RAK; Janagama R; Peruru S; Gajula V; Madathala RR; Chennaiahgari N; Malayala SV
J Med Virol; 2021 Jul; 93(7):4420-4429. PubMed ID: 33822361
[TBL] [Abstract][Full Text] [Related]
8. Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination among healthcare workers: A tertiary hospital experience in Singapore.
Lim SM; Chan HC; Santosa A; Quek SC; Liu EHC; Somani J
Ann Acad Med Singap; 2021 Sep; 50(9):703-711. PubMed ID: 34625758
[TBL] [Abstract][Full Text] [Related]
9. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
10. Are COVID-19 mRNA vaccine side effects severe enough to cause missed work? Cross-sectional study of health care-associated workers.
Cohen DA; Greenberg P; Formanowski B; Parikh PD
Medicine (Baltimore); 2022 Feb; 101(7):e28839. PubMed ID: 35363178
[TBL] [Abstract][Full Text] [Related]
11. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
12. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
[No Abstract] [Full Text] [Related]
13. COVID-19 mRNA Vaccine-induced Pneumonitis.
Matsuzaki S; Kamiya H; Inoshima I; Hirasawa Y; Tago O; Arai M
Intern Med; 2022 Jan; 61(1):81-86. PubMed ID: 34707048
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports.
Mohamed L; Madsen AMR; Schaltz-Buchholzer F; Ostenfeld A; Netea MG; Benn CS; Kofoed PE
BMC Infect Dis; 2021 Dec; 21(1):1264. PubMed ID: 34930152
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers.
Famuyiro TB; Ogunwale A; des Bordes J; Raji M
J Racial Ethn Health Disparities; 2022 Aug; 9(4):1543-1549. PubMed ID: 34264506
[TBL] [Abstract][Full Text] [Related]
17. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
19. Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement.
Grau S; Ferrández O; Martín-García E; Maldonado R
Clin Microbiol Infect; 2021 Nov; 27(11):1698.e1-1698.e4. PubMed ID: 34129908
[TBL] [Abstract][Full Text] [Related]
20. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
